390 related articles for article (PubMed ID: 22946949)
1. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
[TBL] [Abstract][Full Text] [Related]
2. Assessment of regional treatment effect in a multiregional clinical trial.
Tsong Y; Chang WJ; Dong X; Tsou HH
J Biopharm Stat; 2012 Sep; 22(5):1019-36. PubMed ID: 22946947
[TBL] [Abstract][Full Text] [Related]
3. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
Chen CT; Hung HM; Hsiao CF
J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
[TBL] [Abstract][Full Text] [Related]
4. Decision rules and associated sample size planning for regional approval utilizing multiregional clinical trials.
Chen X; Lu N; Nair R; Xu Y; Kang C; Huang Q; Li N; Chen H
J Biopharm Stat; 2012 Sep; 22(5):1001-18. PubMed ID: 22946946
[TBL] [Abstract][Full Text] [Related]
5. Qualitative consistency of treatment effects in multiregional clinical trials.
Tanaka Y; Li G; Wang Y; Chen J
J Biopharm Stat; 2012 Sep; 22(5):988-1000. PubMed ID: 22946945
[TBL] [Abstract][Full Text] [Related]
6. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
7. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
Tsong Y
J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
[No Abstract] [Full Text] [Related]
8. Design and sample size considerations for simultaneous global drug development program.
Huang Q; Chen G; Yuan Z; Lan KK
J Biopharm Stat; 2012 Sep; 22(5):1060-73. PubMed ID: 22946950
[TBL] [Abstract][Full Text] [Related]
9. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
10. Designing multiregional trials under the discrete random effects model.
Lan KK; Pinheiro J; Chen F
J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977
[TBL] [Abstract][Full Text] [Related]
11. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
Huque MF; Alosh M
J Biopharm Stat; 2012; 22(1):160-79. PubMed ID: 22204533
[TBL] [Abstract][Full Text] [Related]
12. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
13. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.
Ando Y; Uyama Y
J Biopharm Stat; 2012 Sep; 22(5):977-87. PubMed ID: 22946944
[TBL] [Abstract][Full Text] [Related]
14. Challenge of multiple co-primary endpoints: a new approach.
Chuang-Stein C; Stryszak P; Dmitrienko A; Offen W
Stat Med; 2007 Mar; 26(6):1181-92. PubMed ID: 16927251
[TBL] [Abstract][Full Text] [Related]
15. Analysis strategies for adaptive designs with multiple endpoints.
Chang M; Chow SC
J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
[TBL] [Abstract][Full Text] [Related]
16. Assessing dose-region profile of drug efficacy: a multiregional trial strategy.
Chen YH; Wang M
J Biopharm Stat; 2012 Sep; 22(5):894-902. PubMed ID: 22946938
[TBL] [Abstract][Full Text] [Related]
17. Partition testing in dose-response studies with multiple endpoints.
Liu Y; Hsu J; Ruberg S
Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
[TBL] [Abstract][Full Text] [Related]
18. How to deal with multiple endpoints in clinical trials.
Neuhäuser M
Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
[TBL] [Abstract][Full Text] [Related]
19. Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials.
Wang SJ; James Hung HM
J Biopharm Stat; 2012 Sep; 22(5):879-93. PubMed ID: 22946937
[TBL] [Abstract][Full Text] [Related]
20. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
Lafaye de Micheaux P; Liquet B; Marque S; Riou J
J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
